Research Grade Vopratelimab (HV702016)

Datasheet Share product Copy info

Price(USD): $

Spec:

100ug
1mg

Number:

Overview
Images
References
Datasheet

Overview

Catalog No.	HV702016
Description	Vopratelimab (HV702016) is a research-grade recombinant antibody targeting CD278. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Humanized
Isotype	IgG1-kappa
Expression system	Mammalian Cells
Clonality	Monoclonal
Target	CD278, ICOS, Inducible T-cell costimulator, Activation-inducible lymphocyte immunomediatory molecule, AILIM
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	Q9Y6W8
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names	JTX-2011, 2039148-04-2
Background	Inducible T-cell costimulator (CD278/ICOS) is a ~22 kDa protein. Stimulatory receptor expressed in activated or antigen-experienced T-cells that plays an important role in the immune response. Upon binding to its ligand ICOSL expressed on antigen presenting cells (APCs), delivers costimulatory signals that enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines including IL10, up-regulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B-cells. Also acts as a costimulatory receptor critical for the differentiation of T follicular regulatory cells upon immune challenges such as viral infection. Mechanistically, potentiates TCR-induced calcium flux by augmenting PLCG1 activation and actin remodeling. In addition, activates PI3K signaling pathways independently of calcium flux. 1. Hutloff, A. et al. (1999) Nature 397, 263-6. PMID: 9930702 2. Rujas, E. et al. (2020) Nature communications 11, 5066. PMID: 33033255 3. Pedros, C. et al. (2016) Nature immunology 17, 825-33. PMID: 27135603 4. Wan, Z. et al. (2020) Cellular & molecular immunology 17, 143-152. PMID: 30523347
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

Bioactivity

SEC-HPLC detection for Research Grade Vopratelimab.
SDS-PAGE

SDS-PAGE for Research Grade Vopratelimab.
Flow CytoMetry

Flow-cytometry using anti-human CD278 antibody. Untransfected cells (blue Histogram) and Transfected cells (Yellow Histogram) were stained with an anti-human CD278 monoclonal antibody (Catalog: HV702016) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer.
Western blot

Western blot analysis was performed using anti-CD278/ICOS monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human CD278/ICOS (Catalog No: HV702011)
Lane 2: negative control